Unknown

Dataset Information

0

Long-term prognostic implications and therapeutic target role of hexokinase II in patients with nasopharyngeal carcinoma.


ABSTRACT: Tumor cells preferentially use anaerobic glycolysis rather than oxidative phosphorylation to generate energy. Hexokinase II (HK-II) is necessary for anaerobic glycolysis and displays aberrant expression in malignant cells. The current study aimed to evaluate the role of HK-II in the survival and biological function of nasopharyngeal carcinoma (NPC). Our study demonstrated that high expression of HK-II was associated with poor survival outcomes in NPC patients. When using 3-BrOP (an HK-II inhibitor) to repress glycolysis, cell proliferation and invasion were attenuated, accompanied by the induction of apoptosis and cell cycle arrest at the G1 stage. Furthermore, 3-BrOP synergized with cisplatin (DDP) to induce NPC cell death. Collectively, we provided that the aberrant expression of HK-II was associated with the malignant phenotype of NPC. A combined treatment modality that targets glycolysis with DDP holds promise for the treatment of NPC patients.

SUBMITTER: Zhang MX 

PROVIDER: S-EPMC5008285 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term prognostic implications and therapeutic target role of hexokinase II in patients with nasopharyngeal carcinoma.

Zhang Meng-Xia MX   Hua Yi-Jun YJ   Wang Hai-Yun HY   Zhou Ling L   Mai Hai-Qiang HQ   Guo Xiang X   Zhao Chong C   Huang Wen-Lin WL   Hong Ming-Huang MH   Chen Ming-Yuan MY  

Oncotarget 20160401 16


Tumor cells preferentially use anaerobic glycolysis rather than oxidative phosphorylation to generate energy. Hexokinase II (HK-II) is necessary for anaerobic glycolysis and displays aberrant expression in malignant cells. The current study aimed to evaluate the role of HK-II in the survival and biological function of nasopharyngeal carcinoma (NPC). Our study demonstrated that high expression of HK-II was associated with poor survival outcomes in NPC patients. When using 3-BrOP (an HK-II inhibit  ...[more]

Similar Datasets

| S-EPMC2944187 | biostudies-literature
| S-EPMC6610758 | biostudies-literature
| S-EPMC7862285 | biostudies-literature
| S-EPMC5348343 | biostudies-literature
| S-EPMC4108430 | biostudies-literature
| S-EPMC4838936 | biostudies-other
| S-EPMC6558473 | biostudies-literature
| S-EPMC4584063 | biostudies-literature
| S-EPMC9220992 | biostudies-literature
| S-EPMC7656546 | biostudies-literature